Physician
New York City Health and Hospitals Corporation
New York City Health and Hospitals Corporation was paid $178.84M by Medicaid between Jan 2018 and Dec 2024, across 728 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 8.7% of everything it billed.
33Billing provider infoNEW YORK CITY HEALTH AND HOSPITALS CORPORATION
BROOKLYN, NY 11203
BROOKLYN, NY 11203
33aNPI1043224355assigned 07/29/2006
33bProvider typeInternal Medicine Physician
28Total paid$178.84M
24GClaims3,786,979
24DCodes billed728
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in New York
Rank by total paid#2 of 6,049
Median peer was paid$11K
This provider vs. median15,809×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KARLIN, MARJI controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 79,041 | $710K | |
| 2019 | 197,002 | $7.42M | |
| 2020 | 545,511 | $27.85M | |
| 2021 | 916,848 | $41.59M | |
| 2022 | 811,880 | $40.91M | |
| 2023 | 650,888 | $32.72M | |
| 2024incomplete | 585,809 | $27.66M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.7% | 176,759 | 152,550 | $15.64M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.5% | 98,891 | 91,765 | $15.25M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.6% | 73,970 | 68,592 | $11.77M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.7% | 93,367 | 83,373 | $10.18M |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 5.4% | 13,842 | 12,300 | $9.64M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.9% | 103,613 | 88,593 | $6.96M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 3.6% | 46,972 | 31,515 | $6.50M |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 3.5% | 160,952 | 20,567 | $6.24M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.2% | 33,871 | 32,364 | $5.77M |
| G0378 | Hospital observation service, per hour | 2.1% | 3,223 | 3,180 | $3.71M |
| S9485 | Crisis intervention mental health services, per diem | 2.0% | 3,125 | 2,560 | $3.53M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 1.7% | 15,788 | 10,045 | $3.04M |
716 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.4% | 34,574 | $2.42M |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 233,164 | $2.20M |
| 99204 | Doctor's office visit, new patient (more involved) | 1.2% | 12,583 | $2.12M |
| 99203 | Doctor's office visit, new patient (routine) | 1.1% | 16,115 | $1.98M |
| 99285 | Emergency room visit (most serious) | 1.1% | 9,985 | $1.98M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.1% | 113,271 | $1.97M |
| 99215 | Doctor's office visit, returning patient (complex) | 1.0% | 12,305 | $1.87M |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | 1.0% | 10,310 | $1.85M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 38,773 | $1.81M |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 10,659 | $1.65M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 25,296 | $1.50M |
| D0999 | Unspecified diagnostic procedure, by report | <1% | 9,318 | $1.49M |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 16,553 | $1.36M |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 12,506 | $1.32M |
| D9999 | Unspecified adjunctive procedure, by report | <1% | 8,244 | $1.18M |
| 99205 | Prolong outpt/office vis | <1% | 5,194 | $1.10M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 22,589 | $1.09M |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 10,430 | $1.08M |
| 80053 | Comprehensive metabolic panel | <1% | 94,475 | $1.06M |
| 99442 | <1% | 19,907 | $997K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 46,307 | $993K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 14,408 | $979K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 5,936 | $933K |
| 81408 | <1% | 694 | $881K | |
| 77336 | <1% | 3,463 | $874K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 20,945 | $802K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 5,606 | $775K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 6,829 | $752K |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 1,149 | $745K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 93 | $745K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 40,542 | $725K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 40,386 | $690K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 6,926 | $669K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 7,308 | $660K |
| 86480 | <1% | 10,609 | $651K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 22,633 | $640K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 8,409 | $628K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 1,333 | $592K |
| 80061 | Lipid panel | <1% | 50,833 | $568K |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 3,195 | $542K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 2,250 | $525K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 41,701 | $519K |
| 95808 | <1% | 803 | $489K | |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 2,424 | $469K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 33,096 | $439K |
| 99441 | <1% | 13,332 | $422K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 56,847 | $420K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 14,764 | $419K |
| 99443 | <1% | 4,965 | $408K | |
| 85027 | <1% | 110,023 | $406K | |
| J1270 | Injection, doxercalciferol, 1 mcg | <1% | 5,282 | $390K |
| 77386 | <1% | 1,725 | $387K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 13,606 | $382K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,340 | $382K |
| 90461 | <1% | 14,948 | $381K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,084 | $335K |
| D0330 | Panoramic radiographic image | <1% | 15,835 | $335K |
| 70486 | <1% | 2,139 | $331K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,721 | $328K |
| 90677 | <1% | 2,467 | $325K | |
| GZ3ZZZZ | <1% | 137 | $322K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 8,756 | $320K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 36,052 | $319K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 8,544 | $317K |
| 86703 | <1% | 22,615 | $312K | |
| 86360 | <1% | 6,560 | $306K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 10,751 | $306K |
| J0401 | Injection, aripiprazole (abilify maintena), 1 mg | <1% | 1,214 | $301K |
| 86850 | <1% | 17,800 | $298K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 2,067 | $291K |
| 59025 | Fetal non-stress test | <1% | 3,076 | $278K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 347 | $266K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 23,093 | $257K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,974 | $255K |
| 90750 | <1% | 2,792 | $252K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 5,141 | $248K |
| D0140 | Limited oral evaluation - problem focused | <1% | 16,917 | $245K |
| 86359 | <1% | 6,545 | $245K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 4,487 | $244K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,206 | $232K |
| 99051 | <1% | 19,510 | $231K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,425 | $226K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,932 | $226K |
| 87535 | <1% | 6,363 | $224K | |
| 12011 | <1% | 1,034 | $222K | |
| 82948 | <1% | 44,382 | $219K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 4,345 | $219K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,764 | $216K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,260 | $212K |
| 99201 | <1% | 2,173 | $207K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 283 | $206K |
| 77290 | <1% | 778 | $206K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 20,039 | $198K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,725 | $196K |
| 12001 | <1% | 828 | $194K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,961 | $194K |
| 0002A | <1% | 6,443 | $193K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,173 | $189K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 27,443 | $183K |
| 0001A | <1% | 6,620 | $181K | |
| J0882 | Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) | <1% | 2,150 | $180K |
| 86901 | <1% | 17,970 | $177K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 2,226 | $173K |
| 76818 | <1% | 1,739 | $172K | |
| 76770 | <1% | 1,303 | $170K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,445 | $169K |
| 90715 | <1% | 8,030 | $169K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 880 | $169K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 674 | $156K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 295 | $153K |
| 81329 | <1% | 1,277 | $150K | |
| 86803 | <1% | 14,728 | $149K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,076 | $149K |
| 76641 | <1% | 1,168 | $147K | |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 2,523 | $144K |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 4,334 | $144K |
| 86900 | <1% | 17,954 | $142K | |
| 83655 | <1% | 13,722 | $140K | |
| 99401 | <1% | 2,296 | $139K | |
| 97162 | <1% | 1,374 | $135K | |
| 10060 | <1% | 720 | $132K | |
| 73610 | <1% | 6,367 | $132K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 836 | $131K |
| 81161 | <1% | 670 | $128K | |
| 90686 | <1% | 12,980 | $127K | |
| 95807 | <1% | 282 | $121K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 4,408 | $119K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 904 | $118K |
| 90697 | <1% | 1,987 | $118K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 2,945 | $114K |
| 81405 | <1% | 596 | $111K | |
| 77065 | Tomosynthesis, mammo | <1% | 951 | $111K |
| 29580 | <1% | 1,433 | $107K | |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 1,686 | $107K |
| J2794 | Injection, risperidone (risperdal consta), 0.5 mg | <1% | 263 | $103K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,365 | $102K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,991 | $101K |
| 73630 | <1% | 5,165 | $100K | |
| 92133 | <1% | 2,228 | $99K | |
| 82805 | <1% | 11,013 | $98K | |
| 90651 | <1% | 1,997 | $97K | |
| 73564 | <1% | 3,711 | $97K | |
| 77066 | Tomosynthesis, mammo | <1% | 600 | $96K |
| 87340 | <1% | 13,385 | $96K | |
| 73130 | <1% | 5,051 | $96K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 2,606 | $95K |
| 11900 | <1% | 637 | $95K | |
| 97802 | <1% | 2,037 | $95K | |
| 0004A | <1% | 2,535 | $94K | |
| 90732 | <1% | 902 | $92K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 1,372 | $92K |
| 81001 | <1% | 43,628 | $90K | |
| 99381 | <1% | 2,940 | $86K | |
| 76536 | <1% | 911 | $86K | |
| 71250 | <1% | 420 | $86K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 633 | $85K |
| 81361 | <1% | 743 | $85K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,494 | $85K |
| 86780 | <1% | 7,977 | $84K | |
| 73110 | <1% | 4,307 | $84K | |
| 86003 | <1% | 1,631 | $81K | |
| 73030 | <1% | 4,218 | $80K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,515 | $78K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 209 | $78K |
| 86706 | <1% | 10,238 | $78K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 142 | $77K |
| 82728 | <1% | 7,213 | $76K | |
| 77412 | <1% | 390 | $76K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 973 | $76K |
| 86769 | <1% | 2,631 | $75K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 8,218 | $75K |
| J1944 | Injection, aripiprazole lauroxil, (aristada), 1 mg | <1% | 404 | $73K |
| 76801 | <1% | 607 | $73K | |
| 84153 | <1% | 4,737 | $73K | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 4,827 | $72K |
| 96127 | <1% | 25,204 | $71K | |
| 84439 | <1% | 10,242 | $71K | |
| 90999 | Dialysis (unlisted procedure) | <1% | 380 | $70K |
| 20610 | <1% | 555 | $69K | |
| 93970 | <1% | 303 | $69K | |
| 12002 | <1% | 295 | $68K | |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | <1% | 1,772 | $68K |
| 92523 | <1% | 293 | $66K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,611 | $66K |
| 90734 | <1% | 1,636 | $66K | |
| 92557 | <1% | 1,455 | $65K | |
| 77062 | <1% | 407 | $64K | |
| 72100 | <1% | 2,227 | $64K | |
| 85610 | <1% | 20,696 | $64K | |
| 83880 | <1% | 4,528 | $64K | |
| 90670 | <1% | 4,151 | $63K | |
| 90836 | <1% | 638 | $63K | |
| J0741 | Injection, cabotegravir and rilpivirine, 2mg/3mg | <1% | 63 | $62K |
| 81243 | <1% | 1,417 | $62K | |
| 96567 | <1% | 102 | $61K | |
| 73590 | <1% | 3,727 | $61K | |
| 81401 | <1% | 691 | $60K | |
| D0120 | Dental checkup, returning patient | <1% | 6,483 | $60K |
| 93247 | <1% | 298 | $60K | |
| 94060 | <1% | 828 | $59K | |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 1,089 | $59K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,023 | $58K |
| 77061 | <1% | 423 | $57K | |
| 93971 | <1% | 993 | $56K | |
| 84702 | <1% | 12,409 | $55K | |
| 88142 | <1% | 2,429 | $55K | |
| 83970 | <1% | 1,712 | $55K | |
| 83020 | <1% | 4,411 | $55K | |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 2,005 | $55K |
| H2001 | Rehabilitation program, per 1/2 day | <1% | 498 | $54K |
| 76813 | <1% | 772 | $53K | |
| 90746 | <1% | 936 | $52K | |
| 86704 | <1% | 6,483 | $52K | |
| 73562 | <1% | 2,528 | $52K | |
| 73560 | <1% | 1,874 | $51K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,218 | $49K |
| 99384 | <1% | 636 | $49K | |
| H2010 | Comprehensive medication services, per 15 minutes | <1% | 746 | $49K |
| 76642 | <1% | 560 | $49K | |
| 83550 | <1% | 8,084 | $48K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12,757 | $48K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 38 | $48K |
| 96367 | <1% | 1,745 | $48K | |
| 81257 | <1% | 716 | $48K | |
| 81025 | <1% | 12,641 | $47K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 169 | $46K |
| 73502 | <1% | 1,884 | $46K | |
| 92567 | <1% | 1,795 | $46K | |
| 99402 | <1% | 621 | $45K | |
| 99383 | <1% | 592 | $45K | |
| H2011 | Crisis intervention service, per 15 minutes | <1% | 236 | $44K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,238 | $44K |
| 73140 | <1% | 2,095 | $44K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 238 | $43K |
| 94726 | <1% | 644 | $43K | |
| 86762 | <1% | 3,397 | $43K | |
| 92134 | <1% | 889 | $42K | |
| 87631 | <1% | 998 | $42K | |
| H0001 | Alcohol and/or drug assessment | <1% | 216 | $40K |
| 86765 | <1% | 3,400 | $39K | |
| 82607 | <1% | 3,334 | $39K | |
| 76870 | <1% | 548 | $38K | |
| 83540 | <1% | 8,199 | $38K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 192 | $38K |
| 84703 | <1% | 11,467 | $38K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 153 | $37K |
| 97161 | <1% | 480 | $37K | |
| 0072A | <1% | 935 | $36K | |
| 90620 | <1% | 1,297 | $36K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,163 | $36K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 164 | $36K |
| D1120 | Dental cleaning, child | <1% | 4,539 | $35K |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 390 | $35K |
| 80076 | <1% | 5,948 | $35K | |
| 86593 | <1% | 10,507 | $34K | |
| D1110 | Prophylaxis - adult | <1% | 2,672 | $34K |
| 86787 | <1% | 3,319 | $34K | |
| 86735 | <1% | 3,177 | $34K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 51 | $34K |
| 0071A | <1% | 972 | $34K | |
| D7240 | Removal of impacted tooth - completely bony | <1% | 346 | $33K |
| 97165 | <1% | 323 | $32K | |
| 85730 | <1% | 14,234 | $32K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 80 | $32K |
| 77263 | <1% | 110 | $32K | |
| 86141 | <1% | 4,118 | $31K | |
| 92083 | <1% | 569 | $30K | |
| 96137 | <1% | 448 | $30K | |
| 86708 | <1% | 3,851 | $30K | |
| 95816 | <1% | 81 | $29K | |
| 90674 | <1% | 1,714 | $29K | |
| 73552 | <1% | 1,664 | $29K | |
| 87536 | <1% | 305 | $29K | |
| 97803 | <1% | 758 | $29K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 49 | $28K |
| 81400 | <1% | 688 | $28K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 469 | $28K |
| 82274 | <1% | 2,341 | $28K | |
| 91320 | <1% | 550 | $28K | |
| 81255 | <1% | 704 | $28K | |
| J2680 | Injection, fluphenazine decanoate, up to 25 mg | <1% | 1,204 | $27K |
| 93975 | <1% | 112 | $27K | |
| 70498 | <1% | 109 | $27K | |
| 94729 | <1% | 467 | $27K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,373 | $27K |
| 82043 | <1% | 5,719 | $27K | |
| 99382 | <1% | 347 | $27K | |
| 73090 | <1% | 2,161 | $26K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,667 | $26K |
| 81251 | <1% | 705 | $25K | |
| 81200 | <1% | 703 | $25K | |
| 82951 | <1% | 2,100 | $25K | |
| 92250 | <1% | 667 | $25K | |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 2,465 | $24K |
| 73620 | <1% | 796 | $24K | |
| 82105 | <1% | 1,773 | $24K | |
| 86709 | <1% | 3,443 | $24K | |
| D9223 | Deep sedation/general anesthesia - each subsequent 15 minute increment | <1% | 552 | $23K |
| 0124A | <1% | 565 | $23K | |
| 92579 | <1% | 417 | $23K | |
| 76000 | <1% | 221 | $23K | |
| 99245 | <1% | 126 | $22K | |
| 72070 | <1% | 679 | $22K | |
| 59425 | <1% | 740 | $22K | |
| 80320 | <1% | 6,822 | $22K | |
| 73080 | <1% | 1,442 | $21K | |
| 81260 | <1% | 702 | $21K | |
| 90480 | <1% | 636 | $21K | |
| 90716 | <1% | 1,831 | $21K | |
| 90707 | <1% | 1,698 | $21K | |
| 90633 | <1% | 2,525 | $20K | |
| H0049 | Alcohol and/or drug screening | <1% | 387 | $20K |
| 97166 | <1% | 204 | $20K | |
| 84146 | <1% | 1,082 | $19K | |
| 36430 | <1% | 93 | $19K | |
| 97010 | <1% | 2,838 | $19K | |
| 93308 | <1% | 258 | $19K | |
| 73700 | <1% | 88 | $19K | |
| 82785 | <1% | 1,324 | $19K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 183 | $19K |
| 96161 | <1% | 3,215 | $19K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 7,360 | $18K |
| 84403 | <1% | 724 | $18K | |
| 0011A | <1% | 1,243 | $18K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 204 | $18K |
| D9222 | <1% | 820 | $18K | |
| 87486 | <1% | 853 | $18K | |
| 86580 | <1% | 3,331 | $17K | |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | <1% | 13 | $17K |
| 71271 | <1% | 84 | $17K | |
| 90681 | <1% | 2,349 | $17K | |
| 83001 | <1% | 939 | $17K | |
| 92555 | <1% | 375 | $17K | |
| 93017 | <1% | 279 | $16K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 562 | $16K |
| D0274 | Bitewings - four radiographic images | <1% | 2,760 | $16K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 560 | $16K |
| 85007 | <1% | 7,045 | $15K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 615 | $15K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,815 | $15K |
| 86160 | <1% | 940 | $15K | |
| 81003 | <1% | 5,618 | $15K | |
| 99385 | <1% | 208 | $15K | |
| 90656 | <1% | 1,254 | $14K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 2,172 | $14K |
| 77080 | <1% | 503 | $14K | |
| 84484 | <1% | 10,875 | $14K | |
| D7230 | <1% | 207 | $14K | |
| 85045 | <1% | 4,901 | $14K | |
| 73060 | <1% | 1,198 | $14K | |
| 87581 | <1% | 853 | $14K | |
| 83735 | <1% | 7,426 | $14K | |
| 92002 | <1% | 168 | $14K | |
| 99408 | <1% | 289 | $14K | |
| 83002 | <1% | 779 | $14K | |
| 87081 | <1% | 2,957 | $14K | |
| 90698 | <1% | 2,105 | $14K | |
| 90694 | <1% | 539 | $14K | |
| 96158 | <1% | 239 | $14K | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 3,597 | $13K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 13 | $13K |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 68 | $13K |
| 76820 | <1% | 303 | $13K | |
| 80165 | <1% | 1,453 | $13K | |
| 36416 | <1% | 658 | $12K | |
| 86592 | <1% | 3,896 | $12K | |
| 84207 | <1% | 448 | $12K | |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) | <1% | 227 | $12K |
| 93246 | <1% | 293 | $12K | |
| 83615 | <1% | 3,036 | $11K | |
| D1206 | Topical application of fluoride varnish | <1% | 2,520 | $11K |
| 96040 | <1% | 189 | $11K | |
| 82570 | <1% | 2,953 | $11K | |
| 72170 | <1% | 724 | $11K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 2,978 | $11K |
| 86008 | <1% | 110 | $11K | |
| 59430 | <1% | 50 | $11K | |
| 87186 | <1% | 3,168 | $11K | |
| 82947 | <1% | 1,572 | $11K | |
| 72190 | <1% | 613 | $11K | |
| 72141 | <1% | 25 | $11K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 10,956 | $10K |
| 84100 | <1% | 5,967 | $10K | |
| 52000 | <1% | 12 | $10K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 13 | $10K |
| 99412 | <1% | 183 | $10K | |
| 54161 | <1% | 14 | $9K | |
| 85651 | <1% | 3,669 | $9K | |
| 31575 | <1% | 75 | $9K | |
| 92015 | Determination of refractive state | <1% | 427 | $9K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 29 | $9K |
| Q3014 | Telehealth originating site facility fee | <1% | 1,243 | $9K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,425 | $9K |
| 77334 | <1% | 50 | $9K | |
| 93976 | <1% | 59 | $9K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,353 | $9K |
| 87538 | <1% | 258 | $8K | |
| 93320 | <1% | 160 | $8K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 14 | $8K |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | <1% | 172 | $8K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12,037 | $8K |
| D9995 | <1% | 341 | $8K | |
| 86225 | <1% | 829 | $8K | |
| 73070 | <1% | 715 | $8K | |
| 90648 | <1% | 1,386 | $8K | |
| 73120 | <1% | 371 | $8K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,388 | $8K |
| 0081A | <1% | 178 | $8K | |
| 90744 | <1% | 951 | $8K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 356 | $8K |
| 86038 | <1% | 921 | $8K | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,382 | $8K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 41 | $8K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 486 | $7K |
| 90653 | <1% | 278 | $7K | |
| 70491 | <1% | 25 | $7K | |
| 83516 | <1% | 542 | $7K | |
| 31231 | <1% | 36 | $7K | |
| 96415 | <1% | 33 | $7K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 454 | $7K |
| 70496 | <1% | 39 | $7K | |
| 84425 | <1% | 393 | $7K | |
| 90661 | <1% | 538 | $7K | |
| 84156 | <1% | 2,336 | $7K | |
| 92551 | <1% | 5,216 | $7K | |
| 87088 | <1% | 912 | $7K | |
| 84436 | <1% | 1,680 | $7K | |
| 77300 | <1% | 62 | $6K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 3,373 | $6K |
| 84445 | <1% | 138 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 235 | $6K |
| 93325 | <1% | 210 | $6K | |
| 86376 | <1% | 457 | $6K | |
| 82803 | <1% | 2,326 | $6K | |
| 90723 | <1% | 998 | $6K | |
| 76814 | <1% | 283 | $6K | |
| H0033 | Oral medication administration, direct observation | <1% | 140 | $6K |
| 85018 | <1% | 2,372 | $6K | |
| D9239 | <1% | 179 | $6K | |
| 0012A | <1% | 278 | $6K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 127 | $6K |
| 96900 | <1% | 202 | $5K | |
| 83690 | <1% | 7,988 | $5K | |
| 73600 | <1% | 278 | $5K | |
| 86235 | <1% | 132 | $5K | |
| 0082A | <1% | 117 | $5K | |
| 84134 | <1% | 459 | $5K | |
| D0272 | Bitewings - two radiographic images | <1% | 1,910 | $5K |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 60 | $5K |
| 87338 | <1% | 452 | $5K | |
| 97168 | <1% | 71 | $5K | |
| 67228 | <1% | 15 | $5K | |
| 92558 | <1% | 269 | $5K | |
| 88304 | <1% | 167 | $5K | |
| 87800 | <1% | 193 | $5K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 50 | $5K |
| 87070 | <1% | 1,337 | $5K | |
| 87517 | <1% | 102 | $5K | |
| 72197 | <1% | 12 | $4K | |
| 77427 | <1% | 22 | $4K | |
| 99406 | <1% | 405 | $4K | |
| 96910 | <1% | 41 | $4K | |
| 96376 | <1% | 2,068 | $4K | |
| 92504 | <1% | 110 | $4K | |
| 90736 | <1% | 32 | $4K | |
| D0603 | <1% | 1,319 | $4K | |
| 99386 | <1% | 39 | $4K | |
| 97116 | <1% | 151 | $4K | |
| 99173 | <1% | 4,791 | $4K | |
| T1023 | Screening to determine the appropriateness of consideration of an individual for participation in a specified program, project or treatment protocol, per encounter | <1% | 67 | $4K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,057 | $4K |
| 82652 | <1% | 102 | $4K | |
| 72131 | <1% | 26 | $4K | |
| 84590 | <1% | 345 | $4K | |
| 82248 | <1% | 1,016 | $4K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 14 | $4K |
| 82784 | <1% | 235 | $4K | |
| 96368 | <1% | 326 | $3K | |
| 87390 | <1% | 507 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,514 | $3K |
| 96380 | <1% | 200 | $3K | |
| 90696 | <1% | 516 | $3K | |
| 83021 | <1% | 527 | $3K | |
| J1741 | Injection, ibuprofen, 100 mg | <1% | 917 | $3K |
| D9243 | <1% | 64 | $3K | |
| 84235 | <1% | 54 | $3K | |
| 96136 | <1% | 39 | $3K | |
| 96156 | <1% | 36 | $3K | |
| 84550 | <1% | 1,185 | $3K | |
| 90710 | <1% | 333 | $3K | |
| 82670 | <1% | 117 | $3K | |
| 82550 | <1% | 1,597 | $3K | |
| 86689 | <1% | 505 | $3K | |
| 93351 | <1% | 13 | $3K | |
| 74019 | <1% | 121 | $3K | |
| 86696 | <1% | 221 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,847 | $3K |
| 87205 | <1% | 1,630 | $3K | |
| 41800 | <1% | 27 | $3K | |
| 0074A | <1% | 71 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,587 | $3K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 662 | $3K |
| 96402 | <1% | 75 | $3K | |
| 82677 | <1% | 112 | $3K | |
| D9430 | <1% | 199 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,668 | $3K |
| 86334 | <1% | 147 | $2K | |
| 90739 | <1% | 17 | $2K | |
| 72040 | <1% | 82 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,944 | $2K |
| 86695 | <1% | 223 | $2K | |
| D2740 | Crown - porcelain/ceramic | <1% | 33 | $2K |
| Q0084 | Chemotherapy administration by infusion technique only, per visit | <1% | 17 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,566 | $2K |
| 87071 | <1% | 609 | $2K | |
| 80178 | <1% | 348 | $2K | |
| 74018 | <1% | 97 | $2K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 12 | $2K |
| 82977 | <1% | 448 | $2K | |
| 1159F | <1% | 16,360 | $2K | |
| 83605 | <1% | 1,163 | $2K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 2,786 | $2K |
| D9110 | <1% | 223 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 708 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,955 | $2K |
| 84402 | <1% | 85 | $2K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,749 | $2K |
| 83883 | <1% | 126 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,442 | $2K |
| 85379 | <1% | 1,311 | $2K | |
| 90717 | <1% | 13 | $2K | |
| 86140 | <1% | 621 | $2K | |
| 76885 | <1% | 13 | $2K | |
| 82375 | <1% | 698 | $2K | |
| 74246 | <1% | 12 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 59 | $2K |
| 99242 | <1% | 43 | $2K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 652 | $2K |
| 12013 | <1% | 13 | $2K | |
| 82010 | <1% | 1,882 | $2K | |
| 90700 | <1% | 219 | $2K | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 9,151 | $2K |
| 73000 | <1% | 92 | $2K | |
| 82330 | <1% | 1,130 | $2K | |
| 86923 | <1% | 77 | $2K | |
| 72128 | <1% | 13 | $2K | |
| 84165 | <1% | 212 | $2K | |
| 70360 | <1% | 86 | $2K | |
| 99429 | <1% | 125 | $2K | |
| 74022 | <1% | 99 | $2K | |
| 87184 | <1% | 270 | $2K | |
| 86336 | <1% | 111 | $1K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 370 | $1K |
| 82810 | <1% | 698 | $1K | |
| 71100 | <1% | 152 | $1K | |
| 82746 | <1% | 144 | $1K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,867 | $1K |
| 96160 | <1% | 150 | $1K | |
| 11721 | <1% | 32 | $1K | |
| 87521 | Neg quan hep c or qual rna | <1% | 44 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,641 | $1K |
| 84480 | <1% | 138 | $1K | |
| 58300 | <1% | 12 | $1K | |
| 92235 | <1% | 12 | $1K | |
| 85384 | <1% | 495 | $1K | |
| 90691 | <1% | 15 | $1K | |
| 72081 | <1% | 29 | $1K | |
| 82962 | <1% | 1,116 | $1K | |
| 71048 | <1% | 72 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 458 | $1K |
| 76775 | <1% | 75 | $1K | |
| 86800 | <1% | 81 | $1K | |
| 0154A | <1% | 35 | $1K | |
| 86255 | <1% | 143 | $1K | |
| 80354 | <1% | 2,251 | $1K | |
| 86320 | <1% | 42 | $1K | |
| 73660 | <1% | 94 | $1K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 12 | $1K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 621 | $1K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,121 | $1K |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 3,261 | $1K |
| 90662 | <1% | 60 | $1K | |
| 3075F | <1% | 19,590 | $1K | |
| 87040 | <1% | 488 | $1K | |
| 84704 | <1% | 67 | $962.70 | |
| 82247 | <1% | 200 | $948.01 | |
| 86430 | <1% | 188 | $909.69 | |
| 94760 | <1% | 1,459 | $903.50 | |
| 80348 | <1% | 87 | $886.87 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,776 | $878.82 |
| 88312 | <1% | 13 | $855.04 | |
| 0502F | <1% | 203 | $849.74 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,022 | $803.50 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 6,838 | $788.66 |
| 76857 | <1% | 12 | $786.36 | |
| D0170 | <1% | 121 | $757.56 | |
| D1351 | Sealant - per tooth | <1% | 81 | $750.75 |
| 87593 | <1% | 20 | $744.36 | |
| D0210 | Intraoral - complete series of radiographic images | <1% | 91 | $740.42 |
| 83050 | <1% | 698 | $739.84 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 628 | $734.65 |
| 98960 | <1% | 22 | $728.15 | |
| 82952 | <1% | 163 | $725.88 | |
| 82627 | <1% | 33 | $695.10 | |
| 80164 | <1% | 69 | $676.46 | |
| S0190 | Mifepristone, oral, 200 mg | <1% | 12 | $667.56 |
| 73100 | <1% | 26 | $626.84 | |
| 82533 | <1% | 39 | $607.19 | |
| 90713 | <1% | 54 | $603.66 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,985 | $589.12 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 250 | $582.00 |
| 86705 | <1% | 74 | $537.83 | |
| 0003A | <1% | 13 | $520.80 | |
| 0031A | <1% | 12 | $519.91 | |
| 88300 | <1% | 49 | $517.54 | |
| 82950 | <1% | 93 | $515.91 | |
| D3330 | Endodontic therapy, molar tooth (excluding final restoration) | <1% | 13 | $514.50 |
| 99451 | <1% | 14 | $511.68 | |
| 84479 | <1% | 121 | $509.16 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 660 | $464.08 |
| 94761 | <1% | 683 | $442.63 | |
| 74021 | <1% | 17 | $434.79 | |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 16 | $417.15 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 464 | $407.05 |
| 81015 | <1% | 172 | $393.93 | |
| 82164 | <1% | 27 | $392.22 | |
| 82955 | <1% | 41 | $387.03 | |
| 73521 | <1% | 13 | $382.04 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 13 | $358.36 |
| 95851 | <1% | 14 | $350.65 | |
| 83498 | <1% | 14 | $350.52 | |
| V2632 | Posterior chamber intraocular lens | <1% | 27 | $349.47 |
| D9990 | <1% | 30 | $341.00 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 132 | $338.23 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 222 | $333.27 |
| 85041 | <1% | 298 | $325.93 | |
| 82042 | <1% | 15 | $325.69 | |
| 51798 | <1% | 13 | $295.89 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,003 | $289.38 |
| 82397 | <1% | 67 | $280.93 | |
| 90381 | <1% | 51 | $278.99 | |
| 85652 | <1% | 159 | $276.90 | |
| 85060 | <1% | 14 | $254.82 | |
| 11720 | <1% | 14 | $253.95 | |
| 90611 | <1% | 224 | $251.81 | |
| 85014 | <1% | 299 | $242.29 | |
| 83010 | <1% | 39 | $232.92 | |
| 80329 | <1% | 51 | $225.48 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 110 | $211.10 |
| 85240 | <1% | 13 | $204.52 | |
| D0270 | <1% | 52 | $198.88 | |
| 87147 | <1% | 37 | $195.20 | |
| D9310 | <1% | 53 | $194.50 | |
| D0602 | <1% | 234 | $192.47 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 26 | $173.12 |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 41 | $171.42 |
| 90685 | <1% | 204 | $169.15 | |
| D0601 | <1% | 435 | $157.86 | |
| 84520 | <1% | 115 | $141.52 | |
| 84154 | <1% | 12 | $134.25 | |
| 84155 | <1% | 34 | $123.95 | |
| D0190 | <1% | 824 | $97.57 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 43 | $96.32 |
| G0008 | Administration of influenza virus vaccine | <1% | 227 | $92.96 |
| 87899 | <1% | 25 | $87.11 | |
| 82565 | <1% | 46 | $81.31 | |
| D9219 | <1% | 22 | $77.54 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 81 | $72.40 |
| 84132 | <1% | 42 | $60.28 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 17 | $59.87 |
| 82465 | <1% | 14 | $58.27 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 42 | $56.43 |
| 81002 | <1% | 21 | $56.16 | |
| 82310 | <1% | 14 | $50.99 | |
| 90380 | <1% | 12 | $50.20 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 92 | $49.11 |
| 82435 | <1% | 39 | $46.40 | |
| D9420 | <1% | 33 | $45.74 | |
| 84295 | <1% | 39 | $41.82 | |
| 82150 | <1% | 33 | $38.56 | |
| 87210 | <1% | 13 | $35.89 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 49 | $28.54 |
| 3078F | <1% | 62,006 | $28.07 | |
| 87075 | <1% | 29 | $19.89 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 26 | $16.51 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 19 | $14.53 |
| 88720 | <1% | 160 | $11.97 | |
| 3074F | <1% | 53,499 | $8.49 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 43 | $8.21 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 14 | $8.02 |
| 3079F | <1% | 20,669 | $7.78 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 31 | $3.75 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 16 | $3.50 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 14 | $1.71 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 26 | $1.04 |
| 3077F | <1% | 16,149 | $0.53 | |
| 1160F | <1% | 11,295 | $0.30 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 25 | $0.08 |
| D1330 | 0% | 818 | $0.00 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | 0% | 26 | $0.00 |
| 3080F | 0% | 6,081 | $0.00 | |
| 3044F | 0% | 154 | $0.00 | |
| 1220F | 0% | 1,455 | $0.00 | |
| 80050 | General health panel | 0% | 479 | $0.00 |
| 44388 | 0% | 35 | $0.00 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 12 | $0.00 |
| 71020 | 0% | 27 | $0.00 | |
| D1310 | 0% | 90 | $0.00 | |
| 99080 | 0% | 4,150 | $0.00 | |
| 99499 | 0% | 5,546 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 212 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 50 | $0.00 |
| 48510 | 0% | 14 | $0.00 | |
| 3725F | 0% | 15 | $0.00 | |
| 2022F | 0% | 28 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 56 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKARLIN, MARJI (CHIEF REVENUE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.